Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms
Summarize this article with:
Biotech Beast9.01K FollowersFollow5ShareSavePlay(10min)CommentsSummaryAurinia Pharmaceuticals Inc. reported another record quarter of Lupkynis net product sales in Q3 '25 of $70.6M.Roche's Gazyva approval introduces a credible competitor, with early physician enthusiasm but uncertain near-term impact on AUPH's market share.AUPH has responded to an FDA request for information on Lupkynis. The response includes new analyses showing a benefit of Lupkynis via metrics other than complete renal response rate. Photodjo/iStock via Getty Images Aurinia Pharmaceuticals Inc. (AUPH) has had an exciting few months, with an earnings update showing continued Lupkynis growth, a competitor's drug being approved for lupus nephritis, and a request for information from the FDA. I rated AUPH aThis article was written byBiotech Beast9.01K FollowersFollowScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.